These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8126248)

  • 61. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 62. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T; Ogawa H; Saito A; Ito A
    Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Renal disease. II. The clinical impact of recombinant human erythropoietin.
    Muirhead N
    J R Coll Physicians Lond; 1997; 31(2):125-30. PubMed ID: 9131506
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Considerations for optimal iron use for anemia due to chronic kidney disease.
    Hudson JQ; Comstock TJ
    Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Non-erythropoietin-based anaemia management in chronic kidney disease.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The role of human recombinant erythropoietin in oncologic surgery].
    Mercuriali F
    Tumori; 1997; 83(4 Suppl 2):S16-9. PubMed ID: 9487379
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management of rHuEPO resistance in CRF patients: a clinical protocol at Winthrop-University Hospital.
    Trenkle JA
    ANNA J; 1998 Jun; 25(3):333-8, 344. PubMed ID: 9801489
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The cardiovascular effects of erythropoietin.
    Smith KJ; Bleyer AJ; Little WC; Sane DC
    Cardiovasc Res; 2003 Sep; 59(3):538-48. PubMed ID: 14499855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Issues related to iron replacement in chronic kidney disease.
    Agarwal R; Warnock D
    Semin Nephrol; 2002 Nov; 22(6):479-87. PubMed ID: 12430092
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis.
    Cotton SL; Holechek MJ
    ANNA J; 1989 Dec; 16(7):463-8. PubMed ID: 2604448
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).
    Macdougall IC
    Nephrol Dial Transplant; 2001; 16 Suppl 3():14-21. PubMed ID: 11402086
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Factors affecting the response to erythropoiesis-stimulating agents].
    Jauréguy M; Choukroun G
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S274-82. PubMed ID: 17373270
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The use of recombinant human erythropoietin (rHuEpo) in humans.
    Adamson JW; Eschbach JW
    Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Erythropoietin: its biological properties and clinical use].
    Ermolenko VM; Nikolaev AIu
    Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979
    [No Abstract]   [Full Text] [Related]  

  • 78. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 79. [Erythropoietin, a milestone in the history of nephrology].
    Uehlinger DE; Frey FJ
    Ther Umsch; 1995 Oct; 52(10):672-7. PubMed ID: 7482378
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.